Literature DB >> 16000949

Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials.

Yukie Harada1, Osamu Imataki, Yuji Heike, Hiroyuki Kawai, Akihiro Shimosaka, Shin-ichiro Mori, Masahiro Kami, Ryuji Tanosaki, Yoshinori Ikarashi, Akira Iizuka, Mitsuji Yoshida, Hiro Wakasugi, Shigeru Saito, Yoichi Takaue, Masao Takei, Tadao Kakizoe.   

Abstract

Valpha24+ NKT is an innate lymphocyte with potential antitumor activity. Clinical applications of Valpha24+ natural killer (NK) T cells, which are innate lymphocytes with potential antitumor activity, require their in vitro expansion. To avoid the potential dangers posed to patients by fetal bovine serum (FBS), the authors evaluated non-FBS culture conditions for the selective and efficient expansion of human Valpha24+ NKT cells. Mononuclear cells (MNCs) and plasma from the peripheral blood of normal healthy donors were used before and after G-CSF mobilization. MNCs and plasma separated from apheresis products were also used. MNCs were cultured for 12 days in AIM-V medium containing alpha-galactosylceramide (alpha-GalCer) (100 ng/mL) and IL-2 (100 U/mL) supplemented with FBS, autologous plasma, or autologous serum. The cultured cells were collected and their surface markers, intracellular cytokines, and cytotoxicity were evaluated. The highest expansion ratio for Valpha24+ NKT cells was obtained from G-CSF-mobilized MNCs cultured in medium containing 5% autologous plasma. Cultures containing MNCs and autologous plasma obtained before and after G-CSF mobilization had approximately 350-fold and 2,000-fold expansion ratios, respectively. These results suggest that G-CSF mobilization conferred a proliferative advantage to Valpha24+ NKT cells by modifying the biology of cells and plasma factors. Expanded Valpha24+ NKT cells retained their surface antigen expression and production of IFN-gamma and exhibited CD1d-independent cytotoxicity against tumor cells. Valpha24+ NKT cells can be efficiently expanded from G-CSF-mobilized peripheral blood MNCs in non-FBS culture conditions with alpha-GalCer and IL-2.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000949     DOI: 10.1097/01.cji.0000163593.66910.ad

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  7 in total

1.  Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.

Authors:  Tonya J Webb; Joan G Bieler; Jonathan P Schneck; Mathias Oelke
Journal:  J Immunol Methods       Date:  2009-05-14       Impact factor: 2.303

2.  Interleukin (IL)-4 promotes T helper type 2-biased natural killer T (NKT) cell expansion, which is regulated by NKT cell-derived interferon-gamma and IL-4.

Authors:  Akira Iizuka; Yoshinori Ikarashi; Mitsuzi Yoshida; Yuji Heike; Kazuyoshi Takeda; Gary Quinn; Hiro Wakasugi; Masanobu Kitagawa; Yoichi Takaue
Journal:  Immunology       Date:  2007-11-14       Impact factor: 7.397

3.  Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells.

Authors:  James E East; Wenji Sun; Tonya J Webb
Journal:  J Vis Exp       Date:  2012-12-29       Impact factor: 1.355

Review 4.  Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential.

Authors:  Christian W Keller; Stefan Freigang; Jan D Lünemann
Journal:  Front Immunol       Date:  2017-05-24       Impact factor: 7.561

5.  Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide.

Authors:  Joanne E Croudace; Stuart M Curbishley; Manuela Mura; Carrie R Willcox; Petr A Illarionov; Gurdyal S Besra; David H Adams; David A Lammas
Journal:  BMC Immunol       Date:  2008-12-03       Impact factor: 3.615

6.  Generation of Human iNKT Cell Lines.

Authors:  Xiangming Li; Moriya Tsuji; Jonathan Schneck; Tonya J Webb
Journal:  Bio Protoc       Date:  2013-03-20

7.  Generation of Mouse iNKT Cell Lines.

Authors:  Xiangming Li; Moriya Tsuji; Jonathan Schneck; Tonya J Webb
Journal:  Bio Protoc       Date:  2013-03-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.